NCT00177190

Completed

In Vitro Evaluation of Immune Responses in Cutaneous T-Cell ...

University of Pittsburgh Source

Compare

Other study identifiers

Sponsor study identifier

0307015

Study Type

observational

Actual enrollment (reported)

8

Locations

1 country

Sites

1

Timeline

Study Start

June 2002

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

January 2005

Actual (reported)

Study Completion

January 2006

Actual (reported)

Brief Summary

This is an in vitro evaluation of cutaneous T-cell lymphoma using patients' blood and tissue to evaluate immune responses related to identified tumor populations and dendritic/CD 8 cells.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 8 participants
Study completion date: January 2006
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
June 2002
Date type not reported
This date has not been verified as actual or estimated.
Primary Completion
January 2005
Actual (reported)
First Submitted
September 12, 2005
Actual (reported)
First Posted
September 15, 2005
Actual (reported)
Study Completion
January 2006
Actual (reported)

Last Updated: May 28, 2014
Status Verified: June 2013
Last Update Submitted: May 27, 2014

Conditions

Cutaneous T-cell Lymphoma Mycosis Fungoides Sezary Syndrome

Keywords

Cutaneous T-cell LymphomaSezary SyndromeMycosis FungoidesImmune Responses

Outcome Measures

Primary Outcomes (1)

Functional capacity of dendritic cells in-vitro
Evaluate the feasibility of the preparation of dendritic cells (DCs), CD8 and Sezary cells (all CD4 positive) in vitro, obtained from the buffy coats or a skin biopsy from an area with tumor involvement of subjects with cutaneous t-cell lymphoma (CTCL) and Sezary syndrome (leukemic stage of CTCL)
At each cell collection

Secondary Outcomes (1)

Evaluate antigen loading of dendritic cells
At each cell collection

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Cutaneous Lymphoma Clinic patients

You may qualify if:

Males or females \<18 years of age

Sponsors & Collaborators

University of Pittsburgh
Otherlead

Study Sites (1)

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, 15213, United States

Biospecimen

Retention: SAMPLES WITHOUT DNA

White cells

MeSH Terms

Conditions

Lymphoma, T-Cell, CutaneousSezary SyndromeMycosis Fungoides

Condition Hierarchy (Ancestors)

Lymphoma, T-CellLymphoma, Non-HodgkinLymphomaNeoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Study Officials

Larisa J. Geskin, M.D.
University of Pittsburgh
PRINCIPAL INVESTIGATOR

Enrollment

8 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Associate Professor of Dermatology

Study Record Dates

First Submitted

September 12, 2005

First Posted

September 15, 2005

Study Start

June 2002

Date type not reported

This date has not been verified as actual or estimated.

NCT00177268

Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

Recruiting

NCT00099593

Immunization Against Tumor Cells in Sezary Syndrome

Phase 2Completed

NCT00050999

Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients

Phase 4Completed

NCT00051012

Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients

Phase 4Completed

NCT07213882

A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)

Early Phase 1Not Yet Recruiting

NCT00047060

Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome

Phase 1/2Completed

Histologically confirmed stage IV cutaneous T-cell lymphoma, with at least 5% of the peripheral blood lymphocytes showing atypical morphology consistent with Sezary cells

Ambulatory and be in stable medical condition

Biopsy positive mycosis fungoides/CTCL or clonal type of CTCL as determined by PCR for TCR and Southern blot for TCR

You may not qualify if:

Received any chemotherapy or radiotherapy within 4 weeks prior to enrollment
Significant psychiatric illness which would prevent adequate informed consent in the opinion of the principal investigator
Systemic steroid therapy other than maintenance for adrenal suppression
Known coagulopathy for non SS subjects.

Contact the study team to confirm eligibility.

Primary Completion

January 2005

Actual (reported)

Study Completion

January 2006

Actual (reported)

Last Updated

May 28, 2014

Record last verified: 2013-06

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00177190
Data provider: ClinicalTrials.gov
Source updated: 2014-05-28
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:28:44 UTC

Locations

US(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

First Submitted

First Posted

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations